Norba Nationals

Main Menu

  • Home
  • Direct Quotation
  • All-in Cost
  • Spontaneous financing
  • Newly Industrializing Country
  • Debt

Norba Nationals

Header Banner

Norba Nationals

  • Home
  • Direct Quotation
  • All-in Cost
  • Spontaneous financing
  • Newly Industrializing Country
  • Debt
Direct Quotation
Home›Direct Quotation›Form 3 CytoDyn Inc. For: May 18 Submitted By: Migliarese Antonio

Form 3 CytoDyn Inc. For: May 18 Submitted By: Migliarese Antonio

By Roy George
May 28, 2021
56
0




Enter Wall Street with StreetInsider Premium. Claim your 1-week free trial here.


FORM 3 UNITED STATES SECURITIES AND EXCHANGES COMMISSION
Washington, DC 20549

INITIAL DECLARATION OF BENEFICIARY OWNERSHIP OF THE SECURITIES

Filed in accordance with Section 16 (a) of the Securities Exchange Act of 1934
or section 30 (h) of the Investment Companies Act 1940

OMB APPROVAL
OMB number: 3235-0104
Expires on: December 31, 2014
Estimated average load
hours per response: 0.5

1. Name and address of the declarant
*


1111 RUE MAIN, SUITE 660

(Street)
2. Date of the declaration requiring the event (month / day / year)
05/18/2021

3. Issuer name
and
Ticker or trading symbol


CytoDyn Inc.
[
CYDY
]
4. Relationship of the reporting person (s) with the issuer

(Check all that apply)
Director 10% owner
X Officer (fill in title below) Other (specify below)
Financial director
5. In case of modification, date of original filing (month / day / year)
6. Individual or joint / group deposit (tick the applicable line)
X Form filed by a declaring person
Form submitted by more than one declarant
Table I – Beneficially owned non-derivative securities
1. Security Title (Instr. 4) 2. Amount of beneficial ownership securities (Instr. 4) 3. Ownership form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of indirect beneficial ownership (Instr. 5)
Table II – Beneficially owned derivative securities
(for example, puts, calls, warrants, options, convertible securities)
1. Title of the derivative title (Instr. 4) 2. Exercise date and expiry date (month / day / year) 3. Title and amount of the securities underlying the derivative security (Instr. 4) 4. Conversion or exercise price of the derivative security 5. Ownership form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of indirect beneficial ownership (Instr. 5)
Exercise date Expiration date Title Amount or number of shares

Unqualified stock option (right to purchase)

01/16/2021 01/16/2030

Ordinary actions

50,000

1.03

re

Unqualified stock option (right to purchase)

02/21/2021 02/21/2030

Ordinary actions

50,000

1.1

re

Unqualified stock option (right to purchase)

07/22/2021 07/22/2030

Ordinary actions

100,000

5.57

re

Unqualified stock option (right to purchase)

02/17/2022 02/17/2031

Ordinary actions

50,000

5.54

re

Explanation of answers:
Arian Colachis, de facto lawyer 05/27/2021
** Signature of the declaring person Dated
Reminder: Report on a separate line for each class of beneficial ownership, directly or indirectly.
* If the form is submitted by more than one declarant,
see

Instruction 4 (b) (v).

** Inaccuracies or intentional omissions of facts constitute federal criminal offenses.
See

18 USC 1001 and 15 USC 78ff (a).

Note: Submit three copies of this form, one of which must be signed manually. If there is not enough space,
see

Instruction 6 for the procedure.

Individuals responding to the collection of information contained in this form are not required to respond unless the form indicates a currently valid OMB number.
LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING KNOW ALL PERSONS BY THESE
PRESENTS, that the undersigned hereby makes, constitutes and appoints
Arian Colachis, SVP and General Counsel and Corporate Secretary of Cytodyn Inc.
(the Company),as the undersigned's true and lawful attorneys-in-fact
(individually, the Attorney-in-Fact), each with full power of substitution and 
resubstitution, with the power to act alone for the undersigned and in
the undersigned's name, place and stead, in any and all capacities to:
1. Prepare, execute in the undersigned's name and on the undersigned's 
behalf, and submit to the Securities and Exchange Commission SEC a Form 
ID, including amendments thereto, and any other documents necessary or 
appropriate to obtain codes and passwords enabling the undersigned to make
electronic filings with the SEC of reports required or considered 
advisable under Section 16 of the Securities Exchange Act of 1934 "the 
Exchange Act" or any rule or regulation of the SEC; 2. Prepare, execute 
and submit to the SEC, any national securities exchange or securities 
quotation system and the Company any and all reports, including any 
amendment thereto, of the undersigned required or considered advisable 
under Section 16 of the Exchange Act and the rules and regulations 
thereunder, with respect to the equity securities of the Company, 
including Forms 3, 4 and 5; and 3. Obtain, as the undersigned's 
representative and on the undersigned's behalf, information regarding
transactions in the Company's equity securities from any third party,
including the Company and any brokers, dealers, employee benefit plan
administrators and trustees, and the undersigned hereby authorizes any
such third party to release any such information to the Attorney-in-Fact.
The undersigned acknowledges that: a) This Limited Power of Attorney 
authorizes, but does not require, the Attorney-in-Fact to act at his or 
her discretion on information provided to such Attorney-in-Fact without 
independent verification of such information; b) Any documents prepared 
or executed by the Attorney-in-Fact on behalf of the undersigned pursuant
to this Limited Power of Attorney will be in such form and will contain
such information as the Attorney-in-Fact, in his or her discretion, deems
necessary or desirable; c) Neither the Company nor the Attorney-in-Fact 
assumes any liability for the undersigned's responsibility to comply with
the requirements of Section 16 of the Exchange Act, any liability of the 
undersigned for any failure to comply with such requirements, or any 
liability of the undersigned for disgorgement of profits under Section 
16b of the Exchange Act; and d) This Limited Power of Attorney does not 
relieve the undersigned from responsibility for compliance with the 
undersigned's obligations under Section 16 of the Exchange Act, 
including, without limitation, the reporting requirements under Section 
16 of the Exchange Act. The undersigned hereby grants to the 
Attorney-in-Fact full power and authority to do and perform each and 
every act and thing requisite, necessary or convenient to be done in 
connection with the foregoing, as fully, to all intents and purposes, 
as the undersigned might or could do in person, hereby ratifying and 
confirming all that the Attorney-in-Fact, or his or her substitute or 
substitutes, shall lawfully do or cause to be done by authority of this 
Limited Power of Attorney. This Limited Power of Attorney shall remain 
in full force and effect until the undersigned is no longer required to 
file Forms 4 or 5 with respect to the undersigned's holdings of and 
transactions in equity securities of the Company, unless earlier 
revoked by the undersigned in a signed writing delivered to the 
Attorney-in-Fact. This Limited Power of Attorney revokes all previous 
powers of attorney with respect to the subject matter of this Limited 
Power of Attorney. 
IN WITNESS WHEREOF, the undersigned has executed this Limited Power of 
Attorney as of May 21, 2021 /s/ Antonio Migliarese



Related posts:

  1. PROPANC BIOPHARMA, INC. : conclusion of a material definitive agreement, creation of a direct financial obligation or obligation under an off-balance sheet arrangement of a holder, financial statements and supporting documents (form 8-K)
  2. Schools need masks, named after Flagler Hospital, Gloria Max and Gale Lemerand
  3. LOWES COMPANIES INC: conclusion of a material definitive agreement, creation of a direct financial obligation or obligation under an off-balance sheet arrangement of a registrant, other events, financial statements and exhibits (Form 8- K)
  4. Q&A with Acting Dean of Students, Dr Gregory Roper
Tagsunited states

Categories

  • All-in Cost
  • Debt
  • Direct Quotation
  • Newly Industrializing Country
  • Spontaneous financing
  • TERMS AND CONDITIONS
  • PRIVACY AND POLICY